(Q35859033)

10 August 2017

1 reference

title

Pharmacological therapy for acromegaly: a critical review (English)

1 reference

10 August 2017

2

Aart Jan Van Der Lely

1 reference

10 August 2017

Alex F Muller

1

1 reference

10 August 2017

publication date

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

64

1 reference

10 August 2017

issue

16

1 reference

10 August 2017

page(s)

1817-1838

1 reference

Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors

10 August 2017

cites work

1 reference

12 December 2020

Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

1 reference

12 December 2020

Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion

1 reference

12 December 2020

Rational design of potent antagonists to the human growth hormone receptor

1 reference

12 December 2020

Determinants of clinical outcome and survival in acromegaly

1 reference

12 December 2020

1 reference

12 December 2020

Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly

1 reference

12 December 2020

Oncological applications of somatostatin analogues

1 reference

12 December 2020

Peptides in the Brain: The New Endocrinology of the Neuron

1 reference

12 December 2020

Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors

1 reference

12 December 2020

Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly

1 reference

12 December 2020

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

1 reference

12 December 2020

Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure.

1 reference

12 December 2020

Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.

1 reference

12 December 2020

Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center

1 reference

12 December 2020

Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.

1 reference

12 December 2020

Psychotic reactions during treatment of pituitary tumours with dopamine agonists

1 reference

12 December 2020

Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone

1 reference

12 December 2020

III. Partial Hypophysectomy for Acromegaly: With Remarks on the Function of the Hypophysis

1 reference

12 December 2020

Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

1 reference

12 December 2020

Radiotherapy in acromegaly: the argument against

1 reference

12 December 2020

Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations

1 reference

12 December 2020

Radiotherapy in acromegaly: a protagonists viewpoint

1 reference

12 December 2020

Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease

1 reference

12 December 2020

CV 205-502 treatment in therapy-resistant acromegalic patients

1 reference

12 December 2020

Acromegaly. Diagnosis and therapy.

1 reference

12 December 2020

CV 205-502 in acromegaly

1 reference

12 December 2020

Classification and nomenclature of somatostatin receptors

1 reference

12 December 2020

Desensitization to somatostatin analogue (Octreotide) observed in a patient with acromegaly

1 reference

12 December 2020

Longterm pergolide treatment of acromegaly.

1 reference

12 December 2020

Tight control of growth hormone: an attainable outcome for acromegaly treatment

1 reference

12 December 2020

Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly

1 reference

12 December 2020

Bromocriptine treatment of acromegaly

1 reference

12 December 2020

Bromocriptine therapy in acromegaly: use in patients resistant to conventional therapy and effect on serum levels of somatomedin C

1 reference

12 December 2020

Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice

1 reference

12 December 2020

Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas

1 reference

12 December 2020

Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage.

1 reference

12 December 2020

1 reference

12 December 2020

Dopaminergic treatment of acromegaly: different effects on hormone secretion and tumor size

1 reference

12 December 2020

Bromocriptine therapy in acromegaly: effects on plasma GH levels, somatomedin-C levels and clinical activity

1 reference

12 December 2020

Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy

1 reference

12 December 2020

Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria

1 reference

12 December 2020

No effect of bromocriptine in acromegaly: a controlled trial

1 reference

12 December 2020

A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal

1 reference

12 December 2020

Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide

1 reference

12 December 2020

Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly

1 reference

12 December 2020

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group

1 reference

12 December 2020

Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR.

1 reference

12 December 2020

The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status

1 reference

12 December 2020

Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide

1 reference

12 December 2020

SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs

1 reference

12 December 2020

Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status

1 reference

12 December 2020

Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues

1 reference

12 December 2020

Human growth hormone and extracellular domain of its receptor: crystal structure of the complex

1 reference

12 December 2020

Crystals of the complex between human growth hormone and the extracellular domain of its receptor

1 reference

12 December 2020

Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors

1 reference

12 December 2020

Human growth hormone and prolactin secreting pituitary adenomas analyzed by in situ hybridization

1 reference

12 December 2020

Effect of octreotide pretreatment on surgical outcome in acromegaly

1 reference

12 December 2020

Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.

1 reference

12 December 2020

Long-term treatment of acromegaly with bromocriptine

1 reference

12 December 2020

Effect of different dopaminergic agents in the treatment of acromegaly

1 reference

12 December 2020

Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients

1 reference

12 December 2020

Dopamine as a Prolactin (PRL) Inhibitor

1 reference

12 December 2020

Growth hormone (GH) responses to arginine and L-dopa alone and after GHRH pretreatment

1 reference

12 December 2020

Functional role of somatostatin receptors in neuroendocrine and immune cells.

1 reference

12 December 2020

Effectiveness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states

1 reference

12 December 2020

Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide

1 reference

12 December 2020

Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient

1 reference

12 December 2020

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration

1 reference

12 December 2020

Reduction of lung distensibility in acromegaly after suppression of growth hormone hypersecretion

1 reference

12 December 2020

Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatil

1 reference

12 December 2020

Novel heptapeptide somatostatin analog displays anti-tumor activity independent of effects on growth hormone secretion

1 reference

12 December 2020

Presurgical Octreotide: treatment in acromegaly

1 reference

12 December 2020

Somatostatin analogs in acromegaly

1 reference

12 December 2020

Regulation of pulsatile growth hormone secretion by fasting in normal subjects and patients with acromegaly

1 reference

12 December 2020

Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis

1 reference

12 December 2020

Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly

1 reference

12 December 2020

Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography

1 reference

12 December 2020

Bromocriptine therapy in eleven patients with acromegaly

1 reference

12 December 2020

Conformational changes required in the human growth hormone receptor for growth hormone signaling.

1 reference

12 December 2020

Effectiveness of a long‐acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas

1 reference

12 December 2020

Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly

1 reference

12 December 2020

Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995).

1 reference

12 December 2020

Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide

1 reference

12 December 2020

1 reference

12 December 2020

Voice changes in acromegaly.

1 reference

12 December 2020

Treatment of acromegaly

1 reference

12 December 2020

FAMILIAL ACROMEGALY: STUDIES IN THREE FAMILIES

1 reference

12 December 2020

Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide

1 reference

12 December 2020

Amino acid residues in the third alpha-helix of growth hormone involved in growth promoting activity

1 reference

12 December 2020

Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly

1 reference

12 December 2020

Drugs five years later. Bromocriptine

1 reference

12 December 2020

Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy

1 reference

12 December 2020

Somatostatin: physiological and clinical significance

1 reference

12 December 2020

The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients

1 reference

12 December 2020

A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein

1 reference

12 December 2020

Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias.

1 reference

12 December 2020

Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group

1 reference

12 December 2020

Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical 'cure'

1 reference

12 December 2020

A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.

1 reference

12 December 2020

Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor

1 reference

12 December 2020

Long-term echocardiographic follow-up of acromegalic heart disease

1 reference

12 December 2020

Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells

1 reference

12 December 2020

Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes

1 reference

12 December 2020

Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study

1 reference

12 December 2020

The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors

1 reference

12 December 2020

Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety

1 reference

12 December 2020

A close correlation between the inhibitory effects of insulin-like growth factor-I and SMS 201-995 on growth hormone release by acromegalic pituitary tumours in vitro and in vivo

1 reference

12 December 2020

Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule

1 reference

12 December 2020

Somatuline Autogel: an extended release lanreotide formulation.

1 reference

12 December 2020

Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly

1 reference

12 December 2020

Clinical results of long-term slow-release lanreotide treatment of acromegaly

1 reference

12 December 2020

Cabergoline in the treatment of acromegaly: a study in 64 patients.

1 reference

12 December 2020

Comparison of the sensitivity of growth hormone secretion to somatostatin in vivo and in vitro in acromegaly

1 reference

12 December 2020

Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer

1 reference

12 December 2020

Criteria for cure of acromegaly: a consensus statement

1 reference

12 December 2020

Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients

1 reference

12 December 2020

Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration

1 reference

12 December 2020

Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).

1 reference

12 December 2020

Insulin-like growth factors and their binding proteins: biological actions

1 reference

12 December 2020

Guidelines for acromegaly management

1 reference

12 December 2020

Octreotide treatment of acromegaly. A randomized, multicenter study

1 reference

12 December 2020

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

1 reference

12 December 2020

Detection of doping with human growth hormone

1 reference

12 December 2020

The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.

1 reference

12 December 2020

Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg).

1 reference

12 December 2020

In vitro and in vivo studies of the antagonistic effects of human growth hormone analogs

1 reference

12 December 2020

Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine

1 reference

12 December 2020

Somatostatin and its receptor family

1 reference

12 December 2020

Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships

1 reference

12 December 2020

Results of a two-year treatment with slow release lanreotide in acromegaly

1 reference

12 December 2020

Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly

1 reference

12 December 2020

Systemic complications of acromegaly: epidemiology, pathogenesis, and management

1 reference

12 December 2020

Somatostatin receptor subtype gene expression in pituitary adenomas

1 reference

12 December 2020

A comparison of lanreotide and octreotide LAR for treatment of acromegaly

1 reference

12 December 2020

Functional antagonism between endogenous mouse growth hormone (GH) and a GH analog results in dwarf transgenic mice

1 reference

12 December 2020

Long-term treatment with 2-Br-alpha-ergocryptine in acromegaly

1 reference

12 December 2020

The role of radiotherapy in acromegaly

1 reference

12 December 2020

Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly.

1 reference

12 December 2020

Octreotide as primary therapy for acromegaly.

1 reference

12 December 2020

Radioimmunoassay for insulin-like growth factor-I: solutions to some potential problems and pitfalls

1 reference

12 December 2020

Mutations in the third alpha-helix of bovine growth hormone dramatically affect its intracellular distribution in vitro and growth enhancement in transgenic mice

1 reference

12 December 2020

Molecular biology of somatostatin receptors

1 reference

12 December 2020

Treatment of acromegaly with dopamine agonists

1 reference

12 December 2020

The human growth hormone receptor. Secretion from Escherichia coli and disulfide bonding pattern of the extracellular binding domain

1 reference

12 December 2020

Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.

1 reference

12 December 2020

Controversy: radiotherapy for acromegaly

1 reference

12 December 2020

Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group

1 reference

12 December 2020

Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size

1 reference

12 December 2020

Growth hormone response to apomorphine, a dopamine receptor agonist, in normal aging and in dementia of the Alzheimer type

1 reference

12 December 2020

Presurgical octreotide treatment in acromegaly

1 reference

12 December 2020

Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation

1 reference

12 December 2020

Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog)

1 reference

12 December 2020

Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.

1 reference

12 December 2020

Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors

1 reference

12 December 2020

Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate

1 reference

12 December 2020

The pathophysiological consequences of somatostatin receptor internalization and resistance

1 reference

12 December 2020

Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy

1 reference

12 December 2020

Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.

1 reference

12 December 2020

1 reference

12 December 2020

Multiple endocrine neoplasia type 1: new clinical and basic findings

1 reference

12 December 2020

Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly

1 reference

12 December 2020

Surgical management of acromegaly

1 reference

12 December 2020

Difficult intubation in acromegalic patients: incidence and predictability.

1 reference

12 December 2020

Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.

1 reference

12 December 2020

Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance

1 reference

12 December 2020

Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation

1 reference

12 December 2020

Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients

1 reference

12 December 2020

Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.

1 reference

12 December 2020

An audit of outcome of treatment in acromegaly.

1 reference

12 December 2020

Lisuride Hydrogen Maleate: Evidence for a Long Lasting Dopaminergic Activity in Humans

1 reference

12 December 2020

Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group

1 reference

12 December 2020

Anaesthetic complications of acromegaly.

1 reference

12 December 2020

Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery

1 reference

12 December 2020

Inhibitory Effect of Dopaminergic Stimulation on GH Release in Acromegaly

1 reference

12 December 2020

Successful treatment of acromegaly with bromocriptine

1 reference

12 December 2020

Molecular pharmacology of somatostatin receptor subtypes

1 reference

12 December 2020

Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group

1 reference

12 December 2020

Bromocriptine treatment in acromegaly: clinical and biochemical effects

1 reference

12 December 2020

Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR).

1 reference

12 December 2020

A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients

1 reference

12 December 2020

Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men.

1 reference

12 December 2020

Long-term treatment of acromegaly with bromocriptine

1 reference

12 December 2020

Somatostatin receptor subtype gene expression in pituitary adenomas

1 reference

12 December 2020

10.2165/00003495-200464160-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

10 August 2017

1052559718

0 references

1 reference